A randomized phase II neoadjuvant (NACT) study of sequential eribulin followed by FAC/FEC-regimen compared to sequential paclitaxel followed by FAC/FEC-regimen in patients (pts) with operable breast cancer not overexpressing HER-2

This article has no abstract
Epistemonikos ID: c1764f31471997d22259fecd98b9922777d6e128
First added on: Feb 07, 2025